Scinopharm Taiwan (TPE:1789) Other Current Payables: NT$364 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
70 GF Score
Price NT$19.85
GF Value NT$27.38
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Other Current Payables?

Scinopharm Taiwan TPE:1789 -3.87% 70 Other Current Payables is NT$364 Mil as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 70/100 and a GF Value™ of NT$27.38 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Scinopharm Taiwan's Other Current Payables for the quarter that ended in Dec. 2025 was NT$364 Mil.

Scinopharm Taiwan's quarterly Other Current Payables declined from Jun. 2025 (NT$592 Mil) to Sep. 2025 (NT$315 Mil) but then increased from Sep. 2025 (NT$315 Mil) to Dec. 2025 (NT$364 Mil).

Scinopharm Taiwan's annual Other Current Payables increased from Dec. 2023 (NT$404 Mil) to Dec. 2024 (NT$498 Mil) but then declined from Dec. 2024 (NT$498 Mil) to Dec. 2025 (NT$364 Mil).

Scinopharm Taiwan Other Current Payables Related Terms

Scinopharm Taiwan Other Current Payables Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Other Current Payables Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 325.82 413.35 403.74 498.19 363.58

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 498.19 364.42 592.07 314.65 363.58
TPE:1789
70GF Score
Scinopharm Taiwan Ltd TPE:1789
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$364 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Other Current Payables of NT$364 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Other Current Payables too high?
Scinopharm Taiwan's current Other Current Payables is NT$364 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Other Current Payables compare to ZTS and UTHR?
Scinopharm Taiwan's Other Current Payables of NT$364 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Other Current Payables is NT$364 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.38, compared to a current price of NT$19.85 — trading 27.5% below its estimated fair value. The current Other Current Payables is NT$364 Mil. Scinopharm Taiwan's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Other Current Payables is NT$364 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$19.85 is trading 27.5% below its estimated GF Value™ of NT$27.38. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Other Current Payables: NT$364 Mil
  • GF Value™: NT$27.38 vs. price of NT$19.85 (27.5% below fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
70GF Score

Get the complete analysis for TPE:1789

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.85
Price
NT$27.38
GF Value